Express Points:
Changing the Course of Outcomes in NSCLC: Immunotherapy Approaches for Early-Stage Disease

Download this short summary slideset to review key takeways on the use of immune checkpoint inhibition for the treatment of resectable early-stage NSCLC.
Justin F. Gainor, MD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 1.08 MB
Released: January 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in biomarker testing for optimal management of advanced NSCLC

Zofia Piotrowska, MD, MHS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 27, 2022 Expired: May 26, 2023

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings